Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Background Laboratory methods that report low-density lipoprotein cholesterol (LDL-C)
include both LDL-C and lipoprotein (a) cholesterol [Lp (a)-C] content. Objectives The …

Importance Lower extremity peripheral artery disease (PAD) affects approximately 8.5
million people in the US and approximately 230 million worldwide. Observations Peripheral …

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …

Background The role of aspirin in reducing lipoprotein (a)-mediated atherothrombotic events
in primary prevention is not established. Objectives This study sought to assess whether low …

Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …

Abstract Lipoprotein (a)[Lp (a)] has risen to the level of an accepted cardiovascular disease
risk factor, but final proof of causality awaits a randomized trial of Lp (a) lowering. Inhibiting …

Background Guidelines recommend nonstatin lipid-lowering agents in patients at very high
risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol …